Overview

A Based on PEEG and PET Study of Anxiolytic Treatment to Improve Cognitive Function in Patients With Alzheimer Disease

Status:
Unknown status

Trial end date:
2018-06-30

Target enrollment:

Participant gender:

Summary

Objective: Evaluation the improvement of the cognitive function of tandospirone add-on treatment on patients with AD comorbid anxiety. Number of Patients: 30 Methodology: Randomized, open-label, parallel-group Assigned Interventions: Experimental: Tandospirone, 30-60 mg/d + Donepezil, 10 mg/d; Control group: Donepezil, 10 mg/d. Effect Evaluation: Primary Outcome: Change from baseline in ADAS-cog total score at week 12; NPI scale total score at week 12;

Phase:

Phase 4

Details

Lead Sponsor:

Zhejiang Provincial People's Hospital
Zhejiang Provincial People’s Hospital

Treatments:

Anti-Anxiety Agents
Donepezil
Tandospirone